Zurich Cantonal Bank
LXEO icon

Zurich Cantonal Bank’s Lexeo Therapeutics LXEO Stock Holding History

Zurich Cantonal Bank’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8K Buy
2,742
+1,387
+102% +$7.5K ﹤0.01% 2487
2026
Q1 		$7.78K Buy
+1,355
New +$9.6K ﹤0.01% 2490

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Zurich Cantonal Bank's LXEO Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Lexeo Therapeutics (LXEO) stake by 102% in Q2 2026, buying an estimated $7.5K and bringing the position to 2,742 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2487.

Zurich Cantonal Bank first reported a position in LXEO in Q1 2026 and has held it in 2 quarters since. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Zurich Cantonal Bank held 2,742 shares of Lexeo Therapeutics worth $12.8K as of Q2 2026.
  • Zurich Cantonal Bank bought 1,387 Lexeo Therapeutics shares in Q2 2026, an estimated $7.5K.
  • Lexeo Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2487 holding.
  • Zurich Cantonal Bank first reported a position in Lexeo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.